Clinical Takeaway
Cannabinoid formulations, particularly CBD-containing products, show measurable reductions in anxiety symptoms across multiple study designs, though effect sizes and optimal dosing vary considerably by formulation and disorder type. Evidence for Tourette syndrome is more limited but suggests potential benefit for tic severity and associated anxiety. Clinicians should interpret these findings cautiously given significant heterogeneity across trials and the need for larger, well-controlled studies before routine clinical application.
#23 Effects of Different Cannabinoid Formulations on Anxiety-Related Disorders, and Tourette Syndrome: A Systematic Review and Meta-Analysis.
Citation: Raminelli Adrieli Oliveira et al.. Effects of Different Cannabinoid Formulations on Anxiety-Related Disorders, and Tourette Syndrome: A Systematic Review and Meta-Analysis.. Cannabis and cannabinoid research. 2025. PMID: 40956670.
Design: 6 Journal: 1 N: 0 Recency: 2 Pop: 2 Human: 1 Risk: -2
This systematic review and meta-analysis provides critical evidence synthesis on cannabinoid efficacy for anxiety disorders and Tourette syndrome, addressing a significant gap as regulatory frameworks expand access to these compounds without robust clinical evidence. The standardized evaluation of different cannabinoid formulations establishes a foundation for evidence-based prescribing practices and helps clinicians distinguish between therapeutic promise and regulatory availability. These findings are essential for informing clinical guidelines and reducing off-label use while better understanding the risk-benefit profile of cannabinoids in mental health treatment.
Quality Gate Alerts:
- Preclinical only
Abstract: Introduction: Cannabinoid formulations have been increasingly proposed as therapeutic potential options for anxiety disorders (ADs). Several countries have expanded regulatory frameworks facilitating access to these compounds due to their alleged therapeutic benefits, including their application in ADs. Given its public health significance, we evaluated existing evidence regarding the efficacy of different medical cannabinoids as interventions for ADs and related mental conditions. Methods: A comprehensive search was conducted in PubMed, Embase, PsycInfo, Web of Science, Scielo, and Lilacs databases. We included randomized controlled trials (RTCs) assessing the effects of various cannabinoid formulations on patients with ADs and related conditions. Distinct meta-analyses were performed for cannabinoid subtypes. Analyses were conducted using Jamovi software, relying on standardized mean difference (SMD) calculations of pre/post-intervention score changes for both intervention and control groups. Results: We incorporated 21 placebo-controlled RCTs, examining cannabinoid interventions in social anxiety disorder (SAD = 5), generalized anxiety disorder (GAD = 1), post-traumatic stress disorder (PTSD = 7), obsessive-compulsive disorder (OCD = 1), and Tourette syndrome (TS = 7). Data extraction indicated considerable heterogeneity across outcomes, including clinical symptoms, neuroimaging findings, well-being, psychosocial functioning, safety, and tolerability. In studies utilizing pure or enriched CBD, the meta-analytic measure indicated a nonsignificant difference (SMD = -0.40; 95% CI: -0.84/0.03). However, a subgroup analysis of pure CBD compounds yielded a moderate, statistically significant effect size (SMD: -0.61, 95% CI: -1.15/-0.07). For studies investigating pure or enriched delta-9-tetrahydrocannabinol (Δ9-THC), the meta-analytic measure was -0.65 (95% CI: -1.06/-0.24), suggesting a moderate, significant effect favoring Δ9-THC-dominant compounds. In meta-analyses
🧠 While this systematic review addresses an important clinical question about cannabinoid formulations for anxiety disorders, several significant caveats warrant careful interpretation by practitioners. The heterogeneity of cannabinoid products (varying CBD to THC ratios, delivery methods, and dosing regimens) combined with the limited number of high-quality randomized controlled trials in this space makes it difficult to draw definitive conclusions about efficacy or to establish standardized treatment protocols. Publication bias and small sample sizes in existing studies likely inflate reported effect sizes, and the review’s inclusion of different anxiety presentations alongside Tourette syndrome suggests underlying methodological complexity that may obscure condition-specific effects. Additionally, the absence of long-term safety data and potential drug interactions with psychiatric medications remain underexplored concerns in most cannabis medicine research. Clinically, while cannabinoids may warrant consideration as adjunctive or alternative options for patients with anxiety who have failed or cannot tolerate conventional first-line agents, practitioners should avoid positioning these compounds as primary interventions and should counsel patients on